Neonatal Osteogenesis Imperfecta: Bisphosphonate Therapy and Fracture Management

Neonatal osteogenesis imperfecta is a rare inherited disorder of bone fragility that can present before birth, at delivery, or during the first weeks of life. Affected babies may sustain fractures with minimal handling, show reduced limb movement, or have a soft, compressible skull. The clinical picture ranges from relatively mild disease to severe forms associated with multiple fractures, deformity and respiratory compromise.

Care requires a coordinated neonatal, orthopaedic, genetics and pain-management approach. Bisphosphonate therapy may reduce bone pain and fracture frequency in selected infants, yet it is not a universal treatment and must be planned around calcium balance, kidney function, feeding, ventilation and the baby’s overall condition. The following principles are particularly relevant to Australian neonatal services and families.

Recognising The Clinical Pattern

Osteogenesis imperfecta results most often from pathogenic changes affecting type I collagen, although several other genes can disrupt bone formation or mineralisation. A family history may be absent because the genetic change can arise spontaneously. Prenatal ultrasound may show shortened or bowed long bones, fractures, poor mineralisation or reduced growth, but milder forms may escape antenatal detection.

After birth, warning signs include unusual irritability during handling, swelling around a limb, asymmetric movement, crepitus, bruising without a clear explanation and fractures seen on radiographs. Blue or grey sclerae, dentinogenesis imperfecta and joint laxity can support the diagnosis, although these features may be subtle in a neonate. Wormian bones on skull imaging and low bone density may also provide useful clues.

A suspected diagnosis should prompt early discussion with a clinical geneticist and a metabolic bone specialist. Molecular testing can identify a collagen-related variant and assist with counselling, while a negative panel does not exclude the condition. Imaging should be clinically justified: repeated radiation exposure is avoided where possible, but a skeletal survey or targeted radiographs may be necessary to document fractures and establish a baseline.

Safe Handling And Initial Fracture Care

The first priority is to reduce pain and prevent additional injury. Staff should support the entire body when lifting, avoid pulling on limbs, and use slow, predictable movements. A baby with suspected fractures should be moved using a padded cot or carefully supported sheet rather than being lifted by the arms or legs. Parents can be taught gentle nappy changes, clothing adjustments and skin-to-skin techniques that maintain alignment.

Fractures are generally managed with comfortable positioning and short-term soft splinting when needed. Rigid casts can cause pressure injury, interfere with circulation and make routine neonatal care difficult, particularly in very small infants. A paediatric orthopaedic team should select the least restrictive support that controls pain and protects the limb. Swelling, colour, warmth, capillary refill and spontaneous movement need regular review.

Analgesia should be individualised and reassessed frequently. Paracetamol may be appropriate for mild pain, while opioids can be required for acute fractures or procedures, with respiratory monitoring in a vulnerable neonate. Non-pharmacological measures, including containment, reduced noise and clustered care, are valuable but should complement rather than replace medication. Feeding fatigue, apnoea and altered responsiveness may indicate pain, medication effects or respiratory disease.

Coordinating Diagnosis And Family Support

Parents often experience shock, guilt and fear after a fracture occurs during ordinary care. Clear explanations are essential: many fractures arise from the underlying bone disorder rather than from parental handling. Conversations should cover what is known, what remains uncertain and how the team will keep the baby comfortable. Genetic counselling can address recurrence risk, testing for parents and implications for future pregnancies.

A multidisciplinary plan may include neonatology, genetics, endocrinology, orthopaedics, physiotherapy, occupational therapy, nursing, pain medicine and palliative care where appropriate. Respiratory assessment is especially important in severe forms because rib fractures, chest wall instability and abnormal bone development can restrict ventilation. Feeding and swallowing support may be needed when weakness, facial structure or repeated procedures interfere with oral intake.

The historical FAOPS meeting site provides useful context for the wider scientific setting in which perinatal medicine develops, including its archived information on FAOPS 2020. Although that Tokyo congress was cancelled during the COVID-19 pandemic, its focus on neonatal and perinatal research reflects the value of sharing protocols for rare disorders across specialist centres.

How Bisphosphonate Therapy Works

Bisphosphonates attach to mineralised bone and reduce osteoclast-mediated bone resorption. In children with moderate or severe osteogenesis imperfecta, intravenous pamidronate has historically been used most often, while intravenous zoledronic acid is used by some specialist services because it can be administered less frequently. Evidence in the neonatal period remains limited and comes largely from small studies, retrospective series and extrapolation from older children.

Treatment is usually considered when there are recurrent fractures, significant bone pain, marked skeletal fragility or severe disease affecting handling and function. It should not be viewed as a way to make fragile bone immediately normal. The expected goals are improved comfort, fewer fractures over time and better tolerance of movement and rehabilitation. Decisions should account for the baby’s age, fracture history, renal status, nutritional intake and respiratory stability.

Before an infusion, clinicians commonly check serum calcium, phosphate, magnesium, alkaline phosphatase, renal function and vitamin D status. Hypocalcaemia should be corrected, and adequate calcium and vitamin D intake should be established. Infants with poor feeding, malabsorption or kidney disease may need a modified plan. The first infusion can cause fever, irritability, transient inflammatory symptoms or changes in calcium levels, so inpatient monitoring is often appropriate.

Families should receive a written schedule explaining why treatment is being offered, what reactions may occur and when urgent review is needed. Bisphosphonate prescribing in Australian infants may be off-label because the Therapeutic Goods Administration indication does not cover every paediatric use. Off-label prescribing is permitted within Australian practice, but the treating clinician remains responsible for appropriate justification, informed consent, documentation and monitoring. Hospital pharmacy and local medicines governance processes should be involved.

Australian Access And Practical Care

Management is concentrated in tertiary paediatric hospitals, such as the Royal Children’s Hospital in Melbourne, Sydney Children’s Hospital and specialist services in Brisbane, Adelaide and Perth. Families living outside major cities may need repeated travel for infusions, imaging and genetic reviews. Telehealth can reduce some appointments, but it cannot replace examination, blood tests or infusion monitoring when the infant is medically unstable.

Australia’s public hospital system may cover much of the acute neonatal and specialist care, while access to particular medicines, genetic tests, orthoses and community therapies can vary between states and territories. The Pharmaceutical Benefits Scheme does not automatically provide every medicine for every rare paediatric indication. Families should ask the hospital social worker, pharmacist and state-based rare disease service about travel assistance, accommodation, equipment and out-of-pocket costs.

Everyday routines also matter. In hot Australian climates, dehydration can complicate feeding and blood-test interpretation, while air conditioning and dry skin can make splints and tapes less comfortable. Families may need practical advice for car seats, prams, sleep positioning and carrying a baby during long drives between regional towns and metropolitan centres. Orthoses, pressure-relieving materials and appropriately sized clothing may need to be sourced through specialised suppliers rather than ordinary retail channels.

Consent and privacy require careful handling. Parents or legal guardians generally provide consent for investigations and treatment, subject to the clinical and legal circumstances of the state or territory. Genetic information should be shared securely and discussed with regard to relatives who may also be at risk. Clinicians should document the indication for off-label bisphosphonate use, alternatives, monitoring arrangements and the family’s understanding of potential benefits and risks.

Monitoring Beyond The First Infusion

Bisphosphonate treatment is only one part of long-term care. Growth, fracture history, pain, mobility, spinal alignment, hearing, dentition, respiratory function and developmental progress should be reviewed over time. The frequency of infusions may change as the child grows and the clinical pattern becomes clearer. Some children require treatment during periods of rapid growth, while others can be observed with supportive care.

Physiotherapy should promote safe movement without forcing range or loading fragile limbs. Occupational therapists can recommend handling strategies, adaptive equipment and positioning that support participation. As the child develops, the team can introduce carefully graded weight-bearing and mobility activities. Prolonged immobilisation should be avoided where safe because it can worsen muscle weakness and reduce bone loading.

Dental review is important because dentinogenesis imperfecta may cause tooth discolouration, rapid wear and sensitivity. Hearing assessment becomes relevant in childhood, and spinal or basilar changes may require specialist surveillance. Families should also receive an emergency plan describing symptoms that warrant urgent review, including sudden limb swelling, severe pain, breathing difficulty, reduced feeding or unusual lethargy.

Research and clinical practice continue to evolve. The archived material on fetal oxygenation monitoring illustrates how perinatal research connects antenatal assessment with neonatal decision-making, although oxygenation monitoring does not diagnose osteogenesis imperfecta or replace genetic and skeletal evaluation.

Australian families should ask for a single written care plan that travels between the neonatal unit, general practitioner, local hospital and tertiary centre. It should list the diagnosis or suspected diagnosis, safe handling instructions, analgesia, allergy information, treating specialists, infusion history and emergency contacts. Sharing this plan with childcare, grandparents and ambulance services can reduce preventable injuries and delays in treatment.

Early specialist referral gives families a clearer path through diagnosis, fracture care and treatment decisions. Neonatal teams can coordinate metabolic bone assessment, genetic counselling and pain management, while parents can keep a record of symptoms, handling concerns and responses to each intervention. For an infant with suspected osteogenesis imperfecta, timely review at an Australian tertiary paediatric service is the safest next step.